Uncategorized
Cross-linking undergoing intense study in U.S.
CHICAGO — Corneal collagen cross-linking, although not approved by the U.S. Food and Drug Administration, is undergoing rigorous study on several fronts, according to a speaker here.“Since this was first presented virtually 2 decades ago, cross-linking has certainly become an accepted modality worldwide for the treatment of keratoconus,” Peter S. Hersh, MD, said during a keynote lecture at the Refractive Surgery Subspecialty Day preceding the American Academy of Ophthalmology meeting. “We as ophthalmologists and patients in the U.S. are looking forward to approval and complete adoption of this important treatment (Read more...)